Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > REGULATORY
REGULATORY
- CSIMC to Set Up New Subcommittee on Medicoeconomic Assessments
April 13, 2012
- CSIMC Approves Listing of Samtirel Without Restriction on Prescription Period
April 12, 2012
- CSIMC Approves 12 APIs/21 Products; Listing Scheduled for April 17
April 12, 2012
- Life Innovation Subcommittee to Recommence Activities, Including 5-Year Strategy: DPJ Project Team
April 12, 2012
- 16 Add’l Prefectures to Participate in Introductory GMP Training Course in Kinki Region
April 11, 2012
- Personnel Exchange Between PMDA, Universities to Facilitate Drafting of GL for Reviewing Innovative Drugs: Deputy Director Miyata of ELD
April 11, 2012
- PMDA to Establish Forum for Discussions Between Reviewers and Outside Researchers to Upgrade Its Ability to Review Cutting-Edge Drugs
April 10, 2012
- MHLW Issues Development Requests for 80 Drugs/Indications with Unmet Medical Needs
April 10, 2012
- MHLW Issues Safety Guidance for First-in-Human Trials
April 10, 2012
- PAFSC to Discuss Approval for Products Including Astellas’s Prostate Cancer Treatment Degarelix
April 9, 2012
- PMDA to Exchange Personnel with Universities, Research Institutes in the Field of Cutting Edge Technologies
April 9, 2012
- MHLW Urges Generic Drug Makers to Ensure Availability of Products for All Indications Approved for Original Drugs
April 6, 2012
- MHLW to Issue 80 Requests for Development of Unapproved Drugs/Indications This Week
April 5, 2012
- Japan to Maintain Drug Pricing System in TPP Talks: Health Minister Komiyama
April 4, 2012
- MHLW Presents Standard Time Frames for Drug Approval Process by Individual Procedure
April 3, 2012
- PMDA Strengthens Consultation System to Support Biomarker Development
April 3, 2012
- MHLW Prepares Q&A to Address Healthcare Professionals’ Concerns About Generic Drugs
April 3, 2012
- DPJ’s PAL Subcommittee to Hold Off Final Recommendation on PAL Amendment Until Late April
April 2, 2012
- MHLW Approves 10 Products Including Pfizer Japan’s Xalkori
April 2, 2012
- CSIMC Recommends Approval of Insurance Coverage for Diagnosis for Xalkori Administration
March 30, 2012
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…